ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes

Molecular medicine (Cambridge, Mass.)

Volumn 20, Issue , 2014, Pages 658-666

  Brines, Michael ^a   Dunne, Ann N ^a   van Velzen, Monique ^a   Proto, Paolo L ^a   Ostenson, Claes Goran ^a   Kirk, Rita I ^a   Petropoulos, Ioannis N ^a   Javed, Saad ^a   Malik, Rayaz A ^a   Cerami, Anthony ^a   Dahan, Albert ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID; OLIGOPEPTIDE; PYROGLUTAMATE HELIX B SURFACE PEPTIDE;

AGED; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; PHASE 2 CLINICAL TRIAL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; OLIGOPEPTIDES;

EID: 84965085480     PISSN: None     EISSN: 15283658     Source Type: Journal    
DOI: 10.2119/molmed.2014.00215     Document Type: Article

References (0)